Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Chua, T. Yan, A. Saxena, D. Morris (2009)
Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?: A Systematic Review of Morbidity and MortalityAnnals of Surgery, 249
D. Elias, D. Goéré, F. Dumont, C. Honoré, P. Dartigues, A. Stoclin, D. Malka, V. Boige, M. Ducreux (2014)
Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases.European journal of cancer, 50 2
Bereder JM Bakrin N (2013)
39:1435—1443
Pierre Dubé, L. Sidéris, Calvin Law, Lloyd Mack, E. Haase, C. Giacomantonio, A. Govindarajan, Monika Krzyzanowska, Pierre Major, Y. McConnell, Walley Temple, R. Younan, J. McCart (2015)
Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms.Current oncology, 22 2
VJ Verwaal RM Smeenk (2007)
Learning curve of combined modality treatment in peritoneal surface diseaseBr J Surg, 94
D. Goéré, D. Malka, D. Tzanis, V. Gava, V. Boige, C. Eveno, L. Maggiori, F. Dumont, M. Ducreux, D. Elias (2013)
Is There a Possibility of a Cure in Patients With Colorectal Peritoneal Carcinomatosis Amenable to Complete Cytoreductive Surgery and Intraperitoneal Chemotherapy?Annals of Surgery, 257
BJ Moran (2006)
Establishment of a peritoneal malignancy treatment center in the United KingdomEur J Surg Oncol, 32
O. Glehen, F. Gilly, C. Arvieux, E. Cotte, F. Boutitie, B. Mansvelt, J. Bereder, G. Lorimier, F. Quénet, D. Elias, Association Chirurgie (2010)
Peritoneal Carcinomatosis from Gastric Cancer: A Multi-Institutional Study of 159 Patients Treated by Cytoreductive Surgery Combined with Perioperative Intraperitoneal ChemotherapyAnnals of Surgical Oncology, 17
G Passot O Glehen (2014)
GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multi-center phase III studyBMC Cancer, 14
Gilly FN Glehen O (2010)
116:5608—5618
T. Yan, M. Deraco, D. Baratti, S. Kusamura, D. Elias, O. Glehen, F. Gilly, E. Levine, P. Shen, F. Mohamed, B. Moran, D. Morris, T. Chua, P. Piso, P. Sugarbaker (2009)
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 36
Naoual Bakrin, J. Bereder, E. Decullier, J. Classe, S. Msika, G. Lorimier, K. Abboud, P. Meeus, G. Ferron, F. Quénet, F. Marchal, S. Gouy, P. Morice, C. Pomel, M. Pocard, F. Guyon, J. Porcheron, O. Glehen (2013)
Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 39 12
L. Sideris P. Dubé (2015)
PMC4399618
Bruin S Verwaal VJ (2008)
15:2426—2432
Gilly FN Glehen O (2010)
17(9):2370—2377
Cecil T Mohamed F (2011)
e84–e96.
Malka D Goéré D (2013)
Jun; 257(6):1065–1071
Goéré D Elias D (2014)
Jan;50(2):332–340
J Esquivel (2014)
Current Status and Future Directions of Hyperthermic Intraperitoneal Chemotherapy (HIPEC)Intervent Oncol 360, 2
D Elias L Maggiori (2010)
Curative treatment of colorectal peritoneal carcinomatosis: current status and future trendsEur J Surg Oncol, 36
W Jarnagin J Tomlinson (2007)
Actual 10-year survival after resection of colorectal liver metastases defines cureJCO, 25
JP Claes S Mulier (2012)
Survival benefit of adding hyperthermic IntraPEritoneal chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidenceCurr Pharm Des, 18
Yan TD Chua TC (2009)
249:900—907
D. Elias, F. Gilly, F. Boutitie, F. Quénet, J. Bereder, B. Mansvelt, G. Lorimier, P. Dubé, O. Glehen (2010)
Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 1
Deraco M Yan TD (2009)
27:6237—6242
Moran BJ. Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy Mohamed F (2009)
May-Jun; 15(3):196–199
Moran BJ Chua TC (2012)
30:2449—2456
SD Richard CW Helm (2010)
Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registryInt J Gynecol Cancer, 20
V. Verwaal, S. Bruin, H. Boot, G. Slooten, H. Tinteren (2008)
8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal CancerAnnals of Surgical Oncology, 15
Gilly F Elias D (2010)
retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28:63—68.
F. Mohamed, T. Cecil, B. Moran, P. Sugarbaker (2011)
A new standard of care for the management of peritoneal surface malignancy.Current oncology, 18 2
O. Glehen, F. Gilly, F. Boutitie, J. Bereder, F. Quénet, L. Sidéris, B. Mansvelt, G. Lorimier, S. Msika, D. Elias (2010)
Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapyCancer, 116
T. Chua, B. Moran, P. Sugarbaker, E. Levine, O. Glehen, F. Gilly, D. Baratti, M. Deraco, D. Elias, A. Sardi, W. Liauw, T. Yan, P. Barrios, A. Portilla, I. Hingh, W. Ceelen, J. Pelz, P. Piso, S. González-Moreno, K. Speeten, D. Morris (2012)
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 20
Souadka A Goéré D (2015)
attempt to define a threshold above which HIPEC does not offer survival benefit: A comparative study. Ann Surg Oncol 2015 Jan 29.
P. Sugarbaker (1996)
Peritonectomy procedures.Cancer treatment and research, 82
PH Sugarbaker (1995)
Peritonectomy proceduresAnn Surg, 221
W. Driel, S. Koole, G. Sonke (2018)
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.The New England journal of medicine, 378 14
D. Goéré, A. Souadka, M. Faron, A. Cloutier, B. Viaña, C. Honoré, F. Dumont, D. Elias (2015)
Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative StudyAnnals of Surgical Oncology, 22
F. Mohamed, B. Moran (2009)
Morbidity and Mortality With Cytoreductive Surgery and Intraperitoneal Chemotherapy: The Importance of a Learning CurveThe Cancer Journal, 15
Abstract Worldwide, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been used for nearly 3 decades to treat peritoneal metastases (PM), improve quality of life, and prolong survival substantially in selected patients. In India, the use of the combined modality of treatment dates back a decade with majority of the efforts taking place within the last 5 years. The first PSOGI workshop (India) held in April 2015, at Bangalore, India offered an opportunity for Indian surgeons performing CRS and HIPEC to share their experience. To study the methodologies of CRS and HIPEC (hospital set up, equipment, training and surgical background) as well as the outcomes in terms of perioperative morbidity and mortality and short and long term survival of patients treated in India, Indian surgeons who had treated at least 10 patients with this combined modality were invited to present their experience. Data collection was retrospective. Analysis of the pooled data was carried out. Eight surgeons treated 384 patients with CRS and HIPEC over a period of 10 years. The commonest primary sites were ovary (as first line therapy n = 124), followed by appendix, including pseudomyxoma peritonei (n = 99), colorectum (n = 77), recurrent ovary (as second line therapy, n = 33), stomach (n = 15), primary peritoneal cancer (n = 10), peritoneal mesothelioma (n = 9) and rare tumors in 17 patients. The weighted mean PCI for all 384 patients was 18.25. 349/384 patients (90.88 %) had a complete cytoreduction (completeness of cytoreduction score of CC-0/1). Grade 3–5 complications developed in 108 patients (27.34 %) and 30 day mortality occurred in 28 (7.29 %) patients. This study showed that CRS and HIPEC can be performed with an acceptable morbidity and mortality in Indian patients. Most of the surgeons are on the learning curve and further improvement in these outcomes is expected over a period of time. Pooling of data related to both common and rare peritoneal cancers would be useful in knowing the disease behavior, response to treatment and outcomes in Indian patients. The 2015 PSOGI meeting provided a unique platform for data presentation with feedback from international experts in the field of peritoneal surface oncology. Future meetings are planned to expand the evaluation of Indian data and progress.
Indian Journal of Surgical Oncology – Springer Journals
Published: Jun 1, 2016
Keywords: surgical oncology; oncology; surgery
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.